Buyout Chatter Lifts TG Therapeutics Shares — But No Deal Confirmed
Unconfirmed buyout speculation tied to Betaville surrounds TG Therapeutics, maker of BRIUMVI for multiple sclerosis. No official deal talks disclosed.
/ 1648 items
#XY↓
Arbutus Biopharma Plans $230 Million Share Buyback After Moderna Patent Win
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
Werewolf and Ambros Merge in $150M Deal to Advance First Potential FDA-Approved Treatment for CRPS-1
Werewolf and Ambros merge in all-stock deal with oversubscribed $150M funding to advance neridronate as potential first FDA-approved CRPS-1 treatment.
Immunocore’s Kimmtrak Anchors Growth as Pipeline Eyes Bigger Markets
Immunocore’s Kimmtrak hit ~$400M in 2025 sales with strong 2026 momentum. Solid cash, advancing Phase 3 trials, and Wall Street Buy ratings signal further upside.
What Makes Nuvation Bio a “Low-Risk, High-Reward” Stock According to Cantor
Cantor Fitzgerald starts coverage of Nuvation Bio at Overweight, citing a low-risk oncology story with upside from Ibtrozi and safusidenib.
Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment
CELZ-201 (Olastrocel) ADAPT trial fully enrolled and treated, including opioid patients. Clean safety profile and meaningful pain relief at 180 days; advancing toward RMAT review.